Last reviewed · How we verify
VenlafaxineXR
Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.
Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.
At a glance
| Generic name | VenlafaxineXR |
|---|---|
| Sponsor | National Institute of Mental Health (NIMH) |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased neurotransmitter concentrations in the synapse. At lower doses it preferentially inhibits serotonin reuptake, while at higher doses it also significantly inhibits norepinephrine reuptake. The extended-release (XR) formulation provides sustained drug levels throughout the day.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Panic disorder
- Vasomotor symptoms associated with menopause
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Somnolence
- Sweating
- Sexual dysfunction
- Hypertension
- Weight gain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |